Étude de l’efficacité thérapeutique et de la tolérance de l’artéméther–luméfantrine et de l’artésunate–amodiaquine au Niger
| Autor: | H Hassan Hamidou, J Hadiza, I Ibrahima, A Mahamadou, Daou Maman, I Yacouba, S Boureima, I Amadou Tidjani, H Kadri Harouna, I Maman Laminou, Eric Adehossi |
|---|---|
| Rok vydání: | 2020 |
| Předmět: |
medicine.medical_specialty
Artemether/lumefantrine biology business.industry Artesunate/amodiaquine Plasmodium falciparum biology.organism_classification Uncomplicated malaria Pathology and Forensic Medicine Internal medicine parasitic diseases medicine Gametocyte Clinical endpoint In patient business Adverse effect medicine.drug |
| Zdroj: | Bulletin de la société de pathologie exotique. 113:17-23 |
| ISSN: | 0037-9085 |
| DOI: | 10.3166/bspe-2020-0120 |
| Popis: | This study aims to evaluate the therapeutic efficacy and tolerance of two ACTs widely used for the treatment of uncomplicated malaria due to Plasmodium falciparum in Niger. The study was conducted from September to November 2017, at the Integrated Health Centers of Dogondoutchi and Birni N'Gaoure, in patients aged from 6 months to 15 years, with uncomplicated malaria due to Plasmodium falciparum. They were treated with either Artemether-Lumefantrine (AL) or Artesunate-Amodiaquine (ASAQ). The primary endpoint was the appropriate clinical and parasitological response (RCPA) to D28, after PCR correction. The secondary criteria were the clearing time of fever, parasites, and gametocytes and then the occurrence of adverse events. A total of 459 patients were examined, of whom 312 patients met the inclusion criteria for therapeutic efficacy evaluation. We have followed 299 patients up to J28 including 146 in the AL arm and 153 in the ASAQ arm. After PCR correction at J28, RCPA were 95.8% and 96% (P = 0.7185) for arms AL and ASAQ, respectively, compared to 93.1% and 94.1% respectively before PCR correction (P = 0.7892). The number of patients on AL and ASAQ treatment who developed an adverse reaction were 6 (7.6%) and 23 (28%) respectively. AL and ASAQ associations are effective and well tolerated. No serious adverse event was noted. However, their monitoring must continue to detect possible resistance. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|